Novel Therapies for Increasing Serum Levels of HDL

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 1, 2009, Pages 151-170

  Toth, Peter P ^a,b  

^a Sterling Rock Falls Clinic Ltd ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cholesterol ester transfer protein inhibitors; High density lipoprotein cholesterol (HDL C); Infusible HDL mimetics; Liver X receptor; PPAR alpha agonists; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APOLIPOPROTEIN A1; ARACHIDONIC ACID; BEZAFIBRATE; CASPASE 3; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CORDAPTIVE; CSL 111; DEXTRO AMINO ACID; ETC 216; FARNESOID X RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GFT 505; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LAROPIPRANT; LAROPRIPRANT; LIVER X RECEPTOR AGONIST; MK 0524 A; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROSTACYCLIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEATH; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIVER FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE;

ANIMALS; ANTILIPEMIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTEROL; CHOLESTEROL, HDL; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL;

EID: 59849107730     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.11.012     Document Type: Review

References (117)

1. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 4 Suppl A (1988) 5A-10A
2. Gotto Jr. A.M., and Brinton E.A. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 43 5 (2004) 717-724
3. Toth P.P. High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. Dis Mon 47 8 (2001) 369-416
4. Wolfram R.M., Brewer H.B., Xue Z., et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 98 6 (2006) 711-717
5. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 6 (1999) 410-418
6. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 102 1 (2000) 21-27
7. Shai I., Rimm E.B., Hankinson S.E., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 110 18 (2004) 2824-2830
8. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 13 (2007) 1301-1310
9. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 2 (2007) 257-260
10. Toth P. Torcetrapib and atherosclerosis: what happened and where do we go from here?. Future Lipidol 2 (2007) 277-284
11. Oram J.F., and Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85 4 (2005) 1343-1372
12. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 9 (2006) 504-511
13. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 3 (2007) 746-756
14. Shao B., Oda M.N., Oram J.F., et al. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21 4 (2006) 322-328
15. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 2 (1995) 211-228
16. Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9 2 (1968) 155-167
17. Brewer Jr. H.B., Remaley A.T., Neufeld E.B., et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24 10 (2004) 1755-1760
18. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 12 (2006) 3090-3100
19. Toth P.P. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr Atheroscler Rep 5 5 (2003) 386-393
20. Yancey P.G., Bortnick A.E., Kellner-Weibel G., et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23 5 (2003) 712-719
21. Wang N., Lan D., Chen W., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101 26 (2004) 9774-9779
22. Wang N., Yvan-Charvet L., Lutjohann D., et al. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J 22 (2008) 1073-1082
23. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 68 (1999) 523-558
24. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108 6 (2001) 793-797
25. Anderson T.J., Gerhard M.D., Meredith I.T., et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75 6 (1995) 71B-74B
26. Li X.P., Zhao S.P., Zhang X.Y., et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 73 3 (2000) 231-236
27. Levkau B., Hermann S., Theilmeier G., et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110 21 (2004) 3355-3359
28. O'Connell B.J., and Genest Jr. J. High-density lipoproteins and endothelial function. Circulation 104 16 (2001) 1978-1983
29. Baker P.W., Rye K.A., Gamble J.R., et al. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 40 2 (1999) 345-353
30. Navab M., Imes S.S., Hama S.Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 6 (1991) 2039-2046
31. Fleisher L.N., Tall A.R., Witte L.D., et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257 12 (1982) 6653-6655
32. Nofer J.R., Levkau B., Wolinska I., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276 37 (2001) 34480-34485
33. Mineo C., Deguchi H., Griffin J.H., et al. Endothelial and antithrombotic actions of HDL. Circ Res 98 11 (2006) 1352-1364
34. Nofer J.R., Walter M., Kehrel B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 18 6 (1998) 861-869
35. Aviram M., and Brook J.G. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 13 6 (1983) 344-350
36. Griffin J.H., Kojima K., Banka C.L., et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 2 (1999) 219-227
37. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
38. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
39. Rubin E.M., Krauss R.M., Spangler E.A., et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 6341 (1991) 265-267
40. Plump A.S., Scott C.J., and Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91 20 (1994) 9607-9611
41. Tangirala R.K., Tsukamoto K., Chun S.H., et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 17 (1999) 1816-1822
42. Pal M., and Pillarisetti S. HDL elevators and mimetics-emerging therapies for atherosclerosis. Cardiovasc Hematol Agents Med Chem 5 1 (2007) 55-66
43. Sirtori C.R., Calabresi L., and Franceschini G. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 142 1 (1999) 29-40
44. Rothblat G.H., Mahlberg F.H., Johnson W.J., et al. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 33 (1992) 1091-1097
45. Duverger N., Kruth H., Emmanuel F., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94 4 (1996) 713-717
46. Paszty C., Maeda N., Verstuyft J., et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 94 2 (1994) 899-903
47. Calabresi L., Tedeschi G., Treu C., et al. Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. J Lipid Res 42 6 (2001) 935-942
48. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 19 5 (1999) 1257-1262
49. Sirtori C.R., Calabresi L., Franceschini G., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103 15 (2001) 1949-1954
50. Shah P.K., Yano J., Reyes O., et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103 25 (2001) 3047-3050
51. Chiesa G., Monteggia E., Marchesi M., et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 90 9 (2002) 974-980
52. Bielicki J.K., and Oda M.N. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41 6 (2002) 2089-2096
53. Toth P.P., and Davidson M.H. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol 19 4 (2004) 374-379
54. Ameli S., Hultgardh-Nilsson A., Cercek B., et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 90 4 (1994) 1935-1941
55. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 4 (1990) 1234-1241
56. Ibanez B.B., Cimmino G., Vilahur G., et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC 216) administration. J Am Coll Cardiol 51 (2008) 1104-1109
57. Li D., Weng S., Yang B., et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 19 2 (1999) 378-383
58. Parolini C., Marchesi M., Lorenzon P., et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I MIlano/1-palmitoyl-2-oleoyl phosphatidylcholine complex) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 51 (2008) 1098-1103
59. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 17 (2003) 2292-2300
60. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 15 (2007) 1675-1682
61. Zhao X.B., and Brown B.G. ApoA-I milano/phospholipids complex. J Am Coll Cardiol 51 (2008) 1110-1111
62. Blanquart C., Barbier O., Fruchart J.C., et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85 2-5 (2003) 267-273
63. Zambon A., Gervois P., Pauletto P., et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 5 (2006) 977-986
64. Bordet R., Gele P., Duriez P., et al. PPARs: a new target for neuroprotection. J Neurol Neurosurg Psychiatr 77 3 (2006) 285-287
65. Fruchart J.C. Novel peroxisome proliferator activated receptor-alpha agonists. Am J Cardiol 100 11A (2007) n41-n46
66. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 8 (2005) 2460-2470
67. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 1 (2001) 53-58
68. Chinetti-Gbaguidi G., Rigamonti E., Helin L., et al. Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J Lipid Res 46 12 (2005) 2717-2725
69. Naik S.U., Wang X., Da Silva J.S., et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113 1 (2006) 90-97
70. Zelcer N., and Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116 3 (2006) 607-614
71. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99 11 (2002) 7604-7609
72. Terasaka N., Hiroshima A., Koieyama T., et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 536 1-3 (2003) 6-11
73. Levin N., Bischoff E.D., Daige C.L., et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 25 1 (2005) 135-142
74. Rader D.J. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 100 11A (2007) n15-n19
75. Li A.C., and Glass C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45 12 (2004) 2161-2173
76. Barter P.J., Brewer Jr. H.B., Chapman M.J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 2 (2003) 160-167
77. Barter P.J., and Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47 3 (2006) 492-499
78. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 13 (2007) 1304-1316
79. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 16 (2007) 1620-1630
80. Krishna R., Anderson M.S., Bergman A.J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370 9603 (2007) 1907-1914
81. Segrest J.P., Li L., Anantharamaiah G.M., et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 11 2 (2000) 105-115
82. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109 25 (2004) 3215-3220
83. Li X., Chyu K.Y., Faria Neto J.R., et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110 12 (2004) 1701-1705
84. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25 7 (2005) 1325-1331
85. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105 3 (2002) 290-292
86. Anantharamaiah G.M., Mishra V.K., Garber D.W., et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 48 9 (2007) 1915-1923
87. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 3 (2003) 352-355
88. Kamanna V.S., and Kashyap M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?. Am J Cardiol 100 11 A (2007) S53-S61
89. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103 17 (2006) 6682-6687
90. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 3 (2004) 411-419
91. Claudel T., Staels B., and Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25 10 (2005) 2020-2030
92. Otte K., Kranz H., Kober I., et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 23 3 (2003) 864-872
93. Bishop-Bailey D., Walsh D.T., and Warner T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A 101 10 (2004) 3668-3673
94. Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109 7 (2002) 961-971
95. Sirvent A., Verhoeven A.J., Jansen H., et al. Farnesoid X receptor represses hepatic lipase gene expression. J Lipid Res 45 11 (2004) 2110-2115
96. Szapary P.O., Wolfe M.L., Bloedon L.T., et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290 6 (2003) 765-772
97. Ulbricht C., Basch E., Szapary P., et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 13 4 (2005) 279-290
98. Ory D.S. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home?. Circ Res 95 7 (2004) 660-670
99. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 100 10 (2007) 1499-1501
100. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 9298 (2001) 2026-2033
101. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 10 (2001) 1108-1113
102. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation 86 3 (1992) 839-848
103. Psaty B.M., Furberg C.D., Kuller L.H., et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults. The Cardiovascular Health Study. Arch Intern Med 159 (1999) 1339-1347
104. Psaty B.M., Anderson M., Kronmal R.A., et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J Am Geriatr Soc 52 10 (2004) 1639-1647
105. Castelli W.P., Doyle T.G., Hames C.G., et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55 5 (1977) 767-772
106. Kannel W.B. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52 4 (1983) 9B-12B
107. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24 11 (2004) 2181-2187
108. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 5 (1988) 641-645
109. Kitamura A., Iso H., Naito Y., et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89 6 (1994) 2533-2539
110. Reed D., and Benfante R. Lipid and lipoprotein predictors of coronary heart disease in elderly men in the Honolulu Heart Program. Ann Epidemiol 2 1-2 (1992) 29-34
111. Gordon D.J., Knoke J., Probstfield J.L., et al. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 74 6 (1986) 1217-1225
112. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
113. Shaten B.J., Kuller L.H., and Neaton J.D. Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years. MRFIT Research Group. Prev Med 20 5 (1991) 655-659
114. Sacco R.L., Benson R.T., Kargman D.E., et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 285 21 (2001) 2729-2735
115. Assmann G., Cullen P., and Schulte H. The Muenster Heart Study (PROCAM), results of follow-up at 8 years. Eur Heart J 19 Suppl A (1998) A2-A11
116. Miller N.E., Thelle D.S., Forde O.H., et al. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1 8019 (1977) 965-968
117. Weijenberg M.P., Feskens E.J., and Kromhout D. Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study. Am J Epidemiol 143 2 (1996) 151-158